Fox Run Management L.L.C. Grows Position in Alkermes plc (NASDAQ:ALKS)

Fox Run Management L.L.C. increased its stake in Alkermes plc (NASDAQ:ALKS - Free Report) by 426.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 66,862 shares of the company's stock after buying an additional 54,172 shares during the period. Alkermes accounts for 0.3% of Fox Run Management L.L.C.'s portfolio, making the stock its 21st largest position. Fox Run Management L.L.C.'s holdings in Alkermes were worth $1,923,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also bought and sold shares of ALKS. CIBC Asset Management Inc raised its holdings in Alkermes by 4.4% in the fourth quarter. CIBC Asset Management Inc now owns 9,155 shares of the company's stock worth $263,000 after purchasing an additional 384 shares in the last quarter. KBC Group NV grew its position in shares of Alkermes by 18.8% in the 3rd quarter. KBC Group NV now owns 4,890 shares of the company's stock worth $137,000 after buying an additional 774 shares during the period. Sei Investments Co. increased its stake in shares of Alkermes by 1.1% in the 4th quarter. Sei Investments Co. now owns 75,394 shares of the company's stock worth $2,168,000 after acquiring an additional 828 shares in the last quarter. EverSource Wealth Advisors LLC lifted its position in Alkermes by 106.2% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,635 shares of the company's stock valued at $47,000 after acquiring an additional 842 shares during the period. Finally, Venturi Wealth Management LLC bought a new stake in Alkermes during the fourth quarter worth about $25,000. 95.21% of the stock is owned by institutional investors.

Remove Ads

Insider Activity

In related news, EVP Craig C. Hopkinson sold 144,419 shares of the stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $35.53, for a total value of $5,131,207.07. Following the completion of the transaction, the executive vice president now owns 57,875 shares of the company's stock, valued at approximately $2,056,298.75. This trade represents a 71.39 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 4.89% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. Royal Bank of Canada started coverage on shares of Alkermes in a report on Thursday, March 13th. They set a "sector perform" rating and a $40.00 target price for the company. UBS Group raised Alkermes from a "sell" rating to a "neutral" rating and boosted their target price for the stock from $21.00 to $38.00 in a report on Tuesday, March 4th. Deutsche Bank Aktiengesellschaft began coverage on Alkermes in a report on Tuesday, February 11th. They set a "buy" rating and a $40.00 price target for the company. HC Wainwright reiterated a "neutral" rating and issued a $46.00 price target on shares of Alkermes in a research note on Thursday, February 13th. Finally, StockNews.com upgraded shares of Alkermes from a "buy" rating to a "strong-buy" rating in a research note on Thursday, February 13th. Four equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, Alkermes currently has a consensus rating of "Moderate Buy" and an average target price of $38.46.

Alkermes Trading Down 0.6 %

ALKS stock traded down $0.19 during trading on Wednesday, reaching $33.69. The stock had a trading volume of 1,451,134 shares, compared to its average volume of 1,697,154. The firm has a market cap of $5.48 billion, a PE ratio of 15.53, a PEG ratio of 2.20 and a beta of 0.62. The stock's 50 day moving average is $33.21 and its two-hundred day moving average is $30.17. Alkermes plc has a 52 week low of $22.90 and a 52 week high of $36.45.

Alkermes (NASDAQ:ALKS - Get Free Report) last posted its quarterly earnings data on Wednesday, February 12th. The company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.81 by $0.11. Alkermes had a return on equity of 30.80% and a net margin of 23.57%. On average, research analysts anticipate that Alkermes plc will post 1.31 EPS for the current year.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.